One Patient's Positive Perspectives

Benlysta's pending FDA approval for lupus

Later this week, on Thursday March 10, 2011, regulators at the the Federal Food & Drug Administration (FDA) are scheduled to rule on the pending recommended U.S. marketing approval of Benlysta.  If approved, this will be the first new drug approved specifically for the treatment of lupus in over 50 years.  Initially expected to be approved in November, 2010, the final decision was postponed to this month.

Benlysta’s approval is likely to help many of the estimated 1.5 million patients in the U.S. with lupus and over 5 million world wide.  The only three drugs currently approved by the FDA for the treatment of systemic lupus are aspirin, prednisone and plaquenil.  This small arsenal of approved drugs is augmented by physicians drawing from drugs approved for other autoimmune diseases, such as rheumatoid arthritis and from cancer and transplant anti-rejection medications.

Successful phase III clinical trials of the biologic drug, Benlysta, were completed involving 2,000 lupus patients and used a new measurement tool for determining the successfulness of the drug in treating lupus.  The FDA approved use of the new measuring approach, that combines aspects of several standard lupus activity measures currently in use by physicians and researchers.

To read more about the pending FDA approval of Benlysta for treatment of lupus, check out these recent articles:

My improvement from Rituxan was dramatic...

Benlysta’s potential approval has a personal side for me.  As a lupus patient who participated in the Phase III clinical trials of Rituxan, I understand the life-changing impacts of a powerful and effective drug treatment.  My improvement after receiving two Rituxan infusions was dramatic, shutting down lupus’ attack on my central nervous system and liver, and greatly quieting the overall activity of my disease for almost five years!

Unfortunately, some lupus patients were not helped by Rituxan, and there were a couple of statistically significant deaths of lupus patients who had received it during the clinical trials.  Research excitement about use of this drug to treat lupus cooled significantly after 2006 when the news of these brain infection related deaths was released.  Although not approved by the FDA for lupus, due to some inconsistent results and these safety concerns, it is now FDA approved and widely used for successful treatment of rheumatoid arthritis.

Although Benlysta is thought to provide less dramatic improvement than what I experienced after receiving Rituxan, it is exciting to finally see the advent of a new drug for lupus.  This may be the first new drug approved for lupus in my lifetime, and it might even be available soon to help me.


Comments on: "Pending FDA approval of new lupus drug Benlysta" (1)

  1. Respect to article author , some superb information .

Your Comments Are Welcome!

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: